Journal Article

FZJ-2019-01610

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Schuepbach, W. M. M. ; Tonder, L. ; Schnitzler, A. ; Krack, P. ; Rau, J. ; Hartmann, A. ; Hälbig, T. ; Pineau, F. ; Falk, A. ; Paschen, L. ; Paschen, S. ; Volkmann, J. ; Dafsari, H. S. ; Barbe, M.FZJ* ; Fink, G. R.FZJ* ; Kühn, A. ; Kupsch, A. ; Schneider, G.-H. ; Seigneuret, E. ; Fraix, V. ; Kistner, A. ; Chaynes, P. P. ; Ory-Magne, F. ; Brefel-Courbon, C. ; Vesper, J. ; Wojtecki, L. ; Derrey, S. ; Maltête, D. ; Damier, P. ; Derkinderen, P. ; Sixel-Döring, F. ; Trenkwalder, C. ; Gharabaghi, A. ; Wächter, T. ; Weiss, D. ; Pinsker, M. O. ; Regis, J.-M. ; Witjas, T. ; Thobois, S. ; Mertens, P. ; Knudsen, K. ; Schade-Brittinger, C. ; Houeto, J.-L. ; Agid, Y. ; Vidailhet, M. ; Timmermann, L. ; Deuschl, G. (Corresponding author)

2019
Ovid [S.l.]

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/21776  doi:10.1212/WNL.0000000000007037

Abstract: Objective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III “off” and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2019

---

Database coverage:
; ; ; Allianz-Lizenz ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---